21642-98-8Relevant articles and documents
DIVALENT NUCLEOBASE COMPOUNDS AND USES THEREFOR
-
Sheet 9/20, (2016/04/19)
Described herein are novel divalent nucleobases that each bind two nucleic acid strands, matched or mismatched when incorporated into a nucleic acid or nucleic acid analog backbone (a genetic recognition reagent, or genetic recognition reagent). In one embodiment, the genetic recognition reagent is a peptide nucleic acid (PNA) or gamma PNA (?PNA) oligomer. Uses of the divalent nucleobases and monomers and genetic recognition reagents containing the divalent nucleobases also are provided.
Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain
Sasikumar,Qiang, Li,Burnett, Duane A.,Greenlee, William J.,Li, Cheng,Heimark, Larry,Pramanik, Birendra,Grilli, Mariagrazia,Bertorelli, Rosalia,Lozza, Gianluca,Reggiani, Angelo
scheme or table, p. 3199 - 3203 (2010/03/03)
Introduction of small unsaturated alkylamino groups at the 4-position of the A-ring of the tricyclic framework (triazafluorenone) afforded extremely potent and selective mGluR1 antagonists with desirable properties. Compounds 11q and 11s are active in the
SUBSTITUTED PYRIDINONES
-
Page/Page column 316-317, (2008/06/13)
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.